AbbVie Inc. (ABBV), Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Earlier, the treatment was first listed, with specific reimbursement criteria, in Ontario and Quebec, and is now publicly funded in almost all the remaining provinces, like Nova Scotia, British Columbia, Saskatchewan, Manitoba, and Newfoundland & Labrador.
The announcement comes shortly after the successful completion of the pan-Canadian Pharmaceutical Alliance Temporary Access Process negotiation.
Currently, AbbVie's stock is trading at $188.52, down 0.18 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.